18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma.
Fiche publication
Date publication
septembre 2018
Journal
Clinical nuclear medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio
Tous les auteurs :
Heimburger C, Bund C, Addeo P, Goichot B, Imperiale A
Lien Pubmed
Résumé
We report the results of F-FDOPA PET/CT in an asymptomatic MEN-1 patient with secreting pituitary prolactinoma investigated before and during dopamine agonists treatment. PET/CT showed intense and focal F-FDOPA uptake in the right part of anterior pituitary corresponding to a microadenoma on MRI imaging. Six months after the beginning of cabergoline, prolactin secretion normalized, pituitary F-FDOPA uptake completely regressed, and tumor size reduced on follow-up PET/CT and MRI, respectively.
Mots clés
Adult, Bone Neoplasms, diagnostic imaging, Dihydroxyphenylalanine, analogs & derivatives, Dopamine Agonists, therapeutic use, Female, Humans, Magnetic Resonance Imaging, Pituitary Neoplasms, diagnostic imaging, Positron-Emission Tomography, Prolactinoma, diagnostic imaging, Radiopharmaceuticals
Référence
Clin Nucl Med. 2018 Sep;43(9):e324-e325